Alpha Paradigm Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alpha Paradigm Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,883	Closed	-$762K	–	550
2022 Q2	$762K	Buy	+4,883	New	+$752K	0.31%	110
2021 Q4	–	Sell	-2,448	Closed	-$319K	–	612
2021 Q3	$319K	Sell	2,448 -5,571	-69%	-$842K	0.13%	254
2021 Q2	$1.42M	Buy	+8,019	New	+$1.39M	0.54%	33

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Alpha Paradigm Partners's JAZZ Position: Q3 2022 in Review

Alpha Paradigm Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 4,883 shares — an estimated $762K sold.

Alpha Paradigm Partners first reported a position in JAZZ in Q2 2021 and held it in 3 quarters. The position peaked at $1.42M in Q2 2021. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

Alpha Paradigm Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Alpha Paradigm Partners sold 4,883 Jazz Pharmaceuticals shares in Q3 2022, an estimated $762K.
Alpha Paradigm Partners first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 3 quarters.
Alpha Paradigm Partners's Jazz Pharmaceuticals position peaked at $1.42M in Q2 2021.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Alpha Paradigm Partners's 13F filing for Q3 2022, filed 15 Nov 2022.